Understanding chronic migraine

Chronic migraine is a highly disabling neurological condition defined as headache occurring on at least 15 days per month for more than three months, with migrainous features present on at least 8 of those days. Patients often experience severe pain, nausea, light and sound sensitivity, cognitive fog, fatigue, and significant functional impairment. Many people with chronic migraine have already tried multiple preventive medications, only to find them ineffective, poorly tolerated, or limited by side effects.

For patients in this situation, interventional treatments such as botulinum toxin type A (Botox) represent an important evidence-based option aimed at reducing headache frequency, severity, and overall disease burden.

The evidence base – the PREEMPT studies

The use of Botox for chronic migraine is underpinned by high-quality clinical evidence, most notably the PREEMPT (Phase III REsearch Evaluating Migraine Prophylaxis Therapy) programme. This consisted of two large, randomised, double-blind, placebo-controlled trials involving over 1,300 patients with chronic migraine.

The PREEMPT studies demonstrated that patients treated with Botox experienced significantly greater reductions in headache-day frequency and migraine-related disability compared with placebo. Importantly, benefit tended to increase with repeated treatment cycles, with many patients achieving their best response after the second or third cycle rather than after the first treatment alone.

These trials led to regulatory approval worldwide and established Botox as the first biologic treatment specifically licensed for the prevention of chronic migraine.

NICE guidance in the UK

In the UK, Botox is recommended by NICE for the prevention of chronic migraine in adults who meet specific criteria. This includes patients who have chronic migraine (≥15 headache days/month, ≥8 migraine days) and who have tried at least three other migraine preventive treatments without adequate benefit, or who have been unable to tolerate them, and who are not overusing acute pain medication.

NICE guidance also provides clear stopping rules to ensure appropriate use. Treatment should be discontinued if there is less than a 30% reduction in headache days after two treatment cycles, or if chronic migraine converts to episodic migraine for a sustained period. These criteria help ensure that Botox is used in a targeted, evidence-based, and patient-centred manner.

How Botox works – the neurogenic theory

Although Botox is widely known for its muscle-relaxing effects, its benefit in migraine is now understood to be predominantly neurogenic rather than muscular. Botox acts on peripheral sensory nerve endings, where it inhibits the release of pain-related neurotransmitters such as CGRP, substance P, and glutamate.

By reducing abnormal peripheral nociceptive input, Botox is thought to decrease peripheral sensitisation and, over time, reduce central sensitisation within the trigeminovascular system. In practical terms, this helps dampen an overactive pain network and reduces the likelihood that everyday triggers will escalate into full migraine attacks.

The Botox treatment protocol

Botox for chronic migraine is administered according to a standardised injection protocol derived from the PREEMPT studies. Treatment typically involves 31 injections across specific muscle groups in the forehead, temples, back of the head, neck, and shoulders, using a total dose of 155 units, with flexibility to tailor certain sites according to the individual pain distribution.

Botox is a preventive treatment rather than an acute pain reliever. Each treatment cycle lasts approximately 12 weeks, after which the effect gradually wears off. Clinical benefit often builds over time, which is why response is usually assessed after at least two to three treatment cycles.

The positives – meaningful and sometimes life-changing benefit

For a significant proportion of patients with chronic migraine, Botox provides substantial and sustained improvement. Responders often experience fewer headache days, reduced pain intensity, and improved function. This can translate into better sleep, improved concentration, greater work reliability, and a reduction in reliance on acute medications.

Many patients describe Botox as life-changing, not because migraine disappears entirely, but because attacks become less frequent, less severe, and more manageable, allowing them to regain control over daily life.

The downsides – the need for ongoing treatment

The main limitation of Botox treatment is that it is not a one-off intervention. To maintain benefit, injections need to be repeated approximately every three months. This requires ongoing commitment and regular follow-up.

The procedure itself involves multiple injections and can be uncomfortable, particularly during the first session, although most patients tolerate it well and find subsequent treatments easier once they know what to expect.

Repeat Botox and antibody formation

Some patients express concern about the possibility of developing tolerance or resistance to Botox over time due to antibody formation. While this is theoretically possible, it appears to be uncommon with the doses and treatment schedules used for migraine.

In our clinical experience at Pain Spa, loss of effectiveness due to antibody-related resistance has not been observed, and many patients continue to derive benefit from repeated treatment cycles over several years when Botox is appropriately indicated.

Side effects and safety

Botox is generally very well tolerated. Most side effects are mild and temporary, including localised tenderness, bruising, or neck discomfort. Less commonly, patients may experience transient neck weakness, shoulder stiffness, or eyelid droop.

Serious complications are rare when Botox is administered by experienced clinicians following established protocols, and side effects often lessen with subsequent treatment cycles.

If Botox does not work – other migraine treatments at Pain Spa

Not all patients respond to Botox, and a lack of response does not mean that treatment options have been exhausted. Pain Spa offers a range of additional interventional treatments tailored to individual headache patterns, including:

• Occipital nerve blocks
• Pulsed radiofrequency ablation of the greater and lesser occipital nerves
• Targeted peripheral nerve blocks for migraine-related pain patterns
• Image-guided cervical and upper thoracic interventions where appropriate
• Multimodal pain management strategies for complex or mixed headache syndromes

The PREDICT study and personalised migraine care

Research such as the PREDICT study has explored whether clinical features and disability scores can help predict which patients are most likely to respond to Botox. Factors such as headache distribution, occipital nerve involvement, and baseline disability may provide useful clues, although no single factor guarantees response.

This growing body of evidence supports a personalised approach to migraine management, reinforcing the importance of specialist assessment, careful phenotyping, and structured follow-up over the first few treatment cycles.

Expert headache management at Pain Spa

Dr Krishna at Pain Spa has extensive experience in managing patients with persistent and complex headache disorders, including chronic migraine. Successful outcomes with Botox depend on accurate diagnosis, careful patient selection, and precise technique.

At Pain Spa, migraine treatment is never one-size-fits-all. Patients who do not respond adequately to Botox are reviewed promptly and offered alternative evidence-based interventions, ensuring an individualised and comprehensive approach to headache care. Please contact Pain Spa at clinic@painspa.co.uk or via our website www.painspa.co.uk.